Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose fenfluramine add-on therapy in myoclonic astatic epilepsy (Doose syndrome)
2018-001664-38Phase 2Completed
- Sponsor
- University Hospital Schleswig-Holstein
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of fenfluramine in myoclonic astatic epilepsy (MAE) and epilepsy, sponsored by University Hospital Schleswig-Holstein. Primary endpoint: Efficacy of add-on fenfluramine in myoclonic astatic epilepsy. Started Apr 2019; status: completed.
02
Drugs
fenfluramine
03
Conditions
myoclonic astatic epilepsy (MAE)epilepsy
Beyond the preview
Go deeper on 2018-001664-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001664-38.